The use of previously Microencapsulated dietary supplements as health promoters in noncommunicable diseases and its development to commercially viable products

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

PACTR

Registry ID

PACTR202507899407559

Enrollment

Registered

2025-07-28

Start date

2023-01-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nutritional, Metabolic, Endocrine

Interventions

Microencapsulated Spirubiotic Sachets

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Ages eligible for study the were 18 Years and older. NCEP ATP111 mentioned at least 3 criteria for diagnosis (BMI =30, WC 40 inch for male, 35 for female, TG more than 150 mg/dL, HDL less than 40 mg/dL, fasting blood glucose more than 100 mg/dL, and blood pressure 130/85 mm HG systolic/diastolic The presence of at least 3 MeS manifestations was confirmed to diagnose MeS

Exclusion criteria

Exclusion criteria: Advanced chronic liver, renal, or respiratory diseases, etc. Currently using nutritional supplements

Design outcomes

Primary

Measure	Time frame
The findings of this study indicate that the administration of spirulina and probiotic bacteria microcapsules as a post-treatment intervention resulted in a noteworthy reduction in total cholesterol (TC), low-density lipoprotein (LDL), and triglyceride (TG) levels. These observed changes have the potential to have a crucial function in the prevention of dyslipidemias. The ingestion of spirulina has been observed to mitigate lipid accumulation within the liver through the mechanism of diminishing the infiltration of macrophages into visceral adipose tissue. Over 12 weeks of consuming spirulina supplements, there was a notable decrease in the increase of body weight, as well as in levels of plasma glucose, insulin, and triglycerides. In the current study, significantly elevated levels of leptin and irisin were observed in the pretreatment-MeS patients in comparison to those in the after-treatment group. The observed decrease in anthropometric measures after treatment was reflected in the level of ghrelin, which was elevated. The levels of catalase, MDA, phosphorus, and zinc exhibited a notable increase in the post-treatment group as opposed to the pre-group. The pre-group exhibited elevated levels of serum liver ?-GT, which subsequently decreased towards the levels considered to be within the normal range in the post-group. The levels of urea and creatinine in both the pre- and post-groups were within normal ranges, suggesting that the utilization of spirulina and probiotic bacteria microcapsules did not pose any significant safety concerns.;The composition of food taken in 24 hr dietary recall was analyzed before and after treatment. Calories consumed by the patient before and after the trial significantly declined (2622±436 and 1932±307 calories/day, respectively) as patients were assigned to some diet advice regimen. Patients documented and observed cuts of sugar thrust and hungry feelings. Analysis of food composition before and after treatment in 24 hr dietary re	—

Measure

Time frame

The findings of this study indicate that the administration of spirulina and probiotic bacteria microcapsules as a post-treatment intervention resulted in a noteworthy reduction in total cholesterol (TC), low-density lipoprotein (LDL), and triglyceride (TG) levels. These observed changes have the potential to have a crucial function in the prevention of dyslipidemias. The ingestion of spirulina has been observed to mitigate lipid accumulation within the liver through the mechanism of diminishing the infiltration of macrophages into visceral adipose tissue. Over 12 weeks of consuming spirulina supplements, there was a notable decrease in the increase of body weight, as well as in levels of plasma glucose, insulin, and triglycerides. In the current study, significantly elevated levels of leptin and irisin were observed in the pretreatment-MeS patients in comparison to those in the after-treatment group. The observed decrease in anthropometric measures after treatment was reflected in the level of ghrelin, which was elevated. The levels of catalase, MDA, phosphorus, and zinc exhibited a notable increase in the post-treatment group as opposed to the pre-group. The pre-group exhibited elevated levels of serum liver ?-GT, which subsequently decreased towards the levels considered to be within the normal range in the post-group. The levels of urea and creatinine in both the pre- and post-groups were within normal ranges, suggesting that the utilization of spirulina and probiotic bacteria microcapsules did not pose any significant safety concerns.;The composition of food taken in 24 hr dietary recall was analyzed before and after treatment. Calories consumed by the patient before and after the trial significantly declined (2622±436 and 1932±307 calories/day, respectively) as patients were assigned to some diet advice regimen. Patients documented and observed cuts of sugar thrust and hungry feelings. Analysis of food composition before and after treatment in 24 hr dietary re

—

Secondary

Measure	Time frame
All anthropometric results showed obesity with BMI =30 in pretreatment. After treatment, patients' measures showed a significant decrease in weight, BMI, WC, and HC.	—

Countries

Egypt

Contacts

Public ContactFatma El Zahraa Abdel Fattah

Researcher

fe.abdelfattahbio@gmail.com+2010026075443

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026